Kinfo
Climb Biotherapeutics, Inc. logo

Climb Biotherapeutics, Inc.

CLYMNASDAQHealthcare·US · USD
$14.00
+0.00 (+0.00%)
Prices as of August 7, 2026 · market closed

Price

Key statistics

Valuation
Market cap801.68M USD
Enterprise value622.30M USD
Trailing P/E-15.92
Forward P/E-13.26
PEG ratio0.45
Price / sales0.00
Price / book4.52
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-18.45%
Return on equity-27.10%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-64.63M USD
Net income-57.62M USD
Diluted EPS-$0.82
Rev. growth (YoY)0.00%
Balance sheet
Total cash183.12M USD
Total debt1.31M USD
Debt / equity0.55
Current ratio31.45
Book value / share$3.10
Cash flow (TTM)
Operating cash flow-52.70M USD
Levered free cash flow-34.04M USD
Shares & price
Shares outstanding47.77M
Float41.56M
Held by institutions65.01%
Beta0.00
50-day MA$12.16
200-day MA$7.12
52-week high$14.53
52-week low$1.54
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.21-0.18+14.29%2026-05-07-0.30-0.20+33.33%2026-03-05-0.21-0.26−23.81%2026-01-300.420.36−14.29%2025-12-05-0.02-0.10−400.00%
About Climb Biotherapeutics, Inc.

Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions. Primarily, it plays a role in advancing treatments for conditions that lack efficient medical solutions, positioning itself at the forefront of innovation in health care. The company's research and product pipeline frequently encompasses diverse therapeutic areas, leveraging cutting-edge technology and research methodologies to target complex biological processes. Climb Biotherapeutics impacts sectors such as pharmaceuticals, medical research, and health services, contributing vital new approaches that could transform patient care standards. Within the financial markets, it holds significance as a biotech entity potentially providing new breakthroughs that may influence industry standards and economic evaluations. By aiming to tackle unmet medical needs, Climb Biotherapeutics is a key player in potentially altering disease management protocols and enhancing health outcomes, thus maintaining a critical role in both the scientific community and the financial ecosystem where health innovation is a focal point of interest.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Employees
28
Headquarters
Wellesley Hills, MA, United States

Frequently asked questions about Climb Biotherapeutics, Inc.